Equities analysts expect that Vericel Corp (NASDAQ:VCEL) will post earnings of $0.02 per share for the current quarter, Zacks reports. Two analysts have made estimates for Vericel’s earnings, with estimates ranging from $0.00 to $0.04. Vericel posted earnings per share of $0.03 in the same quarter last year, which indicates a negative year-over-year growth rate of 33.3%. The firm is expected to announce its next earnings report on Monday, March 4th.
According to Zacks, analysts expect that Vericel will report full year earnings of ($0.42) per share for the current fiscal year, with EPS estimates ranging from ($0.47) to ($0.36). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.12) per share, with EPS estimates ranging from ($0.21) to ($0.02). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Vericel.
Vericel (NASDAQ:VCEL) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.09. The business had revenue of $22.50 million for the quarter, compared to analyst estimates of $18.14 million. Vericel had a negative net margin of 23.35% and a negative return on equity of 37.86%. The business’s quarterly revenue was up 57.3% compared to the same quarter last year.
VCEL has been the topic of several analyst reports. LADENBURG THALM/SH SH upgraded shares of Vericel from a “neutral” rating to a “buy” rating in a research report on Monday, July 16th. BTIG Research reiterated a “buy” rating and set a $17.00 price target on shares of Vericel in a research report on Tuesday, August 7th. Needham & Company LLC reduced their price target on shares of Vericel from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, August 8th. Finally, BidaskClub lowered shares of Vericel from a “hold” rating to a “sell” rating in a research report on Tuesday, October 23rd. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $16.75.
Shares of NASDAQ VCEL traded up $0.44 during trading hours on Wednesday, hitting $17.09. 2,834,400 shares of the stock were exchanged, compared to its average volume of 1,092,130. The company has a current ratio of 7.72, a quick ratio of 7.48 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $513.57 million, a price-to-earnings ratio of -34.18 and a beta of 3.36. Vericel has a 1-year low of $3.63 and a 1-year high of $17.36.
In related news, CFO Gerard J. Michel sold 15,000 shares of the stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $12.35, for a total value of $185,250.00. Following the completion of the transaction, the chief financial officer now owns 165,960 shares of the company’s stock, valued at approximately $2,049,606. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Steven C. Gilman sold 9,000 shares of the stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $12.03, for a total transaction of $108,270.00. Following the completion of the transaction, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $108,270. The disclosure for this sale can be found here. In the last three months, insiders sold 114,000 shares of company stock valued at $1,609,770. 4.70% of the stock is owned by insiders.
Large investors have recently modified their holdings of the stock. Raymond James Financial Services Advisors Inc. bought a new position in Vericel in the 2nd quarter valued at approximately $487,000. Rhumbline Advisers bought a new position in Vericel in the 2nd quarter valued at approximately $340,000. Castleark Management LLC lifted its stake in Vericel by 27.2% in the 2nd quarter. Castleark Management LLC now owns 720,585 shares of the biotechnology company’s stock valued at $6,990,000 after purchasing an additional 154,068 shares during the last quarter. JPMorgan Chase & Co. bought a new position in Vericel in the 1st quarter valued at approximately $845,000. Finally, First Washington CORP lifted its stake in Vericel by 18.7% in the 2nd quarter. First Washington CORP now owns 656,550 shares of the biotechnology company’s stock valued at $6,369,000 after purchasing an additional 103,380 shares during the last quarter. 76.57% of the stock is owned by institutional investors and hedge funds.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.
See Also: Hedge Funds – Risk or Reward?
Get a free copy of the Zacks research report on Vericel (VCEL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.